Massachusetts Society of Clinical Oncologists - FDA approves nivolumab (Opdivo) plus ipilimumab (Yervoy) and chemotherapy for first-line treatment of metastatic NSCLC

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA approves nivolumab (Opdivo) plus ipilimumab (Yervoy) and chemotherapy for first-line treatment of metastatic NSCLC

FDA approves nivolumab (Opdivo) plus ipilimumab (Yervoy) and chemotherapy for first-line treatment of metastatic NSCLC

27 May 2020 9:44 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org